Metformin induces apoptosis and cell cycle arrest mediated by oxidative stress, AMPK and FOXO3a in MCF-7 breast cancer cells

PLoS ONE

Volumn 9, Issue 5, 2014, Pages

  Queiroz, Eveline A I F ^a,b   Puukila, Stephanie ^d   Eichler, Rosangela ^a   Sampaio, Sandra C ^a   Forsyth, Heidi L ^d   Lees, Simon J ^d   Barbosa, Aneli M ^c   Dekker, Robert F H ^c   Fortes, Zuleica B ^a   Khaper, Neelam ^d  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b STATE UNIVERSITY OF LONDRINA   (Brazil)

^c LAKEHEAD UNIVERSITY   (Canada)

^d LAKEHEAD UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE 3; CATALASE; COPPER ZINC SUPEROXIDE DISMUTASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; INSULIN RECEPTOR; INSULIN RECEPTOR BETA; MANGANESE SUPEROXIDE DISMUTASE; METFORMIN; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE P38; PROTEIN BAX; PROTEIN BCL 2; PROTEIN KINASE B; PROTEIN P27; S6 KINASE; TRANSCRIPTION FACTOR FKHRL1; UNCLASSIFIED DRUG; ANTIDIABETIC AGENT; FORKHEAD TRANSCRIPTION FACTOR; FOXO3 PROTEIN, HUMAN; HYDROGEN; OXIDIZING AGENT; TUMOR PROTEIN;

ANIMAL CELL; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; BREAST CANCER; CELL CYCLE ARREST; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL DEATH; CELL VIABILITY; CONTROLLED STUDY; DRUG MECHANISM; ENZYME PHOSPHORYLATION; GENE EXPRESSION; HUMAN; HUMAN CELL; MCF 7 CELL LINE; NONHUMAN; OXIDATIVE STRESS; PROTEIN EXPRESSION; RAT; BREAST TUMOR; DRUG EFFECTS; ENZYME ACTIVATION; FEMALE; G1 PHASE CELL CYCLE CHECKPOINT; GENETICS; METABOLISM; PATHOLOGY; TUMOR CELL LINE;

AMP-ACTIVATED PROTEIN KINASES; APOPTOSIS; BREAST NEOPLASMS; CELL LINE, TUMOR; ENZYME ACTIVATION; FEMALE; FORKHEAD TRANSCRIPTION FACTORS; G0 PHASE; G1 PHASE CELL CYCLE CHECKPOINTS; HUMANS; HYDROGEN; HYPOGLYCEMIC AGENTS; METFORMIN; NEOPLASM PROTEINS; OXIDANTS; OXIDATIVE STRESS;

EID: 84901463217     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0098207     Document Type: Article

References (75)

1. GLOBOCAN database (2008) Available: http://globocan.iarc.fr. Accessed 03 October 2012.
2. Brazilian National Cancer Institute - INCA (2012) Available: http://www.inca.gov.br/estimativa/2012/index.asp?ID=2 Accessed 28 August 2012.
3. Bowker Sl, Majundar SR, Veugelers P, Johnson JA (2006) Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin. Diabetes Care 29: 254-258.
4. Evans JMM, Donnely LA, Emslle-Smith AM, Alessi DR, Morris AD (2005) Metformin and reduced risk of cancer in diabetic patients. Brit Med J 330: 1304-1305. (Pubitemid 40813563)
5. Ropelle ER, Pauli JR, Zecchin KG, Ueno M, Souza CT, et al. (2007) A central role for neuronal adenosine 59-monophosphate-activated protein kinase in cancer-induced anorexia. Endocrinology 148: 5220-5229. (Pubitemid 350012623)
6. Franciosi M, Lucisano G, Lapice E, Strippoli GFM, Pellegrini A, et al. (2013) Metformin therapy and risk of cancer in patients with type 2 diabetes: Systematic review. PLOS ONE 8: 1-13.
7. Giannarelli R, Aragona M, Coppelli A, Del Prato S (2003) Reducing insulin resistance with metformin: the evidence today. Diabetes Metab 29: 6S28-35.
8. Rena G, Pearson ER, Sakamoto K (2013) Molecular mechanisms of action of metformin: old or new insights. Diabetologia 56: 1898-1906.
9. Fonseca EAI, Oliveira MA, Lobato NS, Akamine EH, Colquhoun A, et al. (2011) Meformin reduces the stimulatory effect of obesity on in vivo Walker-256 tumor development and increases the area of tumor necrosis. Life Sci 88: 846-852.
10. Pollak M (2007) Insulin, insulin-like growth factors, insulin resistance, and neoplasia. Am J Clin Nutr 86: 820S-822S.
11. Pollak M (2013) Potential applications for biguanides in oncology. J Clin Invest 123: 3693-3700.
12. Zhang X, Tang N, Hadden TJ, Rishi AK (2011) Akt, FoxO and regulation of apoptosis. Biochim Biophys Actahttp://www.ncbi.nlm.nih.gov/pubmed/21440011 1813: 1978-1986.
13. Algire C, Zakikhani M, Blouin M, Shuai JH, Pollak M (2008) Metformin attenuates the stimulatory effect of a high-energy diet on in vivo LLC1 carcinoma growth. Endocr-Relat Cancer 15: 833-839.
14. Berstein LM, Yue W, Wang JP, Santen RJ (2010) Isolated and combined action of tamoxifen and metformin in wild-type, tamoxifen-resistant, and estrogen-deprived MCF-7 cells. Breast Cancer Res Treat 128: 109-117.
15. Zakikhani M, Dowling R, Fantus G, Sonenberg N, Pollak M (2006) Metformin is an AMP kinase-dependent growth inhibitor for breast cancer cells. Cancer Res 66: 10269-10273. (Pubitemid 44799743)
16. Zakikhani M, Dowling RJO, Sonenberg N, Pollak MN (2008) The effects of adiponectin and metformin on prostate and colon neoplasia involve activation of AMP-activated protein kinase. Cancer Prev Res 1: 369-375.
17. Liang J, Shao SH, Zu ZX, Hennessy B, Ding Z, et al. (2007) The energy sensing LKB1-AMPK pathway regulates p27(kip1) phosphorylation mediating the decision to enter autophagy or apoptosis. Nat Cell Biol 9: 218-224. (Pubitemid 46420865)
18. Chiacchiera F, Maltrone A, Ferrari E, Ingravallo G, Lo Sasso G, et al. (2009) p38alpha blockade inhibits colorectal cancer growth in vivo by inducing a switch from hif1alpha- to foxo-dependent transcription. Cell Death Differ 16: 1203-1214.
19. Greer EL, Banko MR, Brunet A (2009) AMP-activated protein kinase and FoxO transcription factors in dietary restriction-induced longevity. Ann N Y Acad Sci 1170: 688-692.
20. Calnan DR, Brunet A (2008) The FoxO code. Oncogene 27: 2276-2288. (Pubitemid 351501779)
21. Chiacchiera F, Simone C (2009) Inhibition of p38alpha unveils an AMPK-FoxO3A axis linking autophagy to cancer-specific metabolism. Autophagy 5: 1030-1033.
22. Brunet A, Bonni A, Zigmond MJ, Lin MZ, Juo P, et al. (1999) Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor. Cell 96: 857-868. (Pubitemid 29165088)
23. Dijkers PF, Medemadagger RH, Lammers JJ, Koenderman l, Coffer PJ (2000) Expression of the pro-apoptotic bcl-2 family member bim is regulated by the forkhead transcription factor FKHR-L1. Curr Biol 10: 1201-1204.
24. Malumbres M, Barbacid M (2009) Cell Cycle, CDKs and cancer: a changing paradigm. Nat Rev Cancer 9: 153-66.
25. Fuchs-Tarlocsky V (2013) Role of antioxidants in cancer therapy. Nutrition 29: 15-21.
26. Hull RN (1953) Establishing long-term cultures of mammalian normal, solid tumor, and ascites tumor cells on glass. Science 117: 223-225.
27. Lees SJ, Childs TE, Booth FW (2008) p21 (Cip1) expression is increased in ambient oxygen, compared to estimated physiological (5%) levels in rat muscle. Cell Prolif 41: 193-207 (Pubitemid 351367489)
28. Pick E, Keisari Y (1980) A simple colorimetric method for the measurement of hydrogen peroxide produced by cells in culture. J Immunol Methods 38: 161-170. (Pubitemid 11251411)
29. Pick E, Mizel D (1981) Rapid microassays for the measurement of superoxide and hydrogen peroxide production by macrophages in culture using automatic enzyme immunoassay reader. J Immunol Methods 46: 211-226. (Pubitemid 11020859)
30. Hundal RS, Inzucchi SE (2003) Metformin: new understandings, new uses. Drugs 63: 1879-94. (Pubitemid 37108399)
31. Kahn BB, Alquier T, Carling D, Hardie DG (2005) AMP-activated protein kinase: Ancient energy gauge provides clues to modern understanding of metabolism. Cell Metabolism 1: 15-25. (Pubitemid 43960587)
32. Seufert J, Lubben G, Dietrich K, Bates PC (2004) A comparison of the effects of thiazolidinediones and metformin on metabolic control in patients with type 2 diabetes mellitus. Clin Ther 26: 805-218.
33. Hursting SD, Hursting MJ (2012) Growth signals, inflammation, and vascular perturbations: mechanistic links between obesity, metabolic syndrome, and cancer. Arterioscler Thromb Vasc Biol 32: 1766-1770.
34. Kaaks R, Lukanova A, Kurzer MS (2002) Obesity, endogenous hormones, and endometrial cancer risk: a synthetic review. Cancer Epidemiol Biomarkers Prev 11: 1531-1543. (Pubitemid 36020003)
35. Kaaks R (1996) Nutrition, hormones, and breast cancer: is insulin the missing link? Cancer Cause Control 7: 605-625.
36. Sahra IB, Laurent K, Loubat A, Giorgetti-Peraldi S, Colosetti P, et al. (2008) The antidiabetic drug metformin exerts an antitumoral effect in vitro and in vivo through a decrease of cyclin D1 level. Oncogene 27: 3576-3586. (Pubitemid 351793803)
37. Buzzai M, Jones RG, Amaravadi RK, Lum JJ, DeBerardinis RJ, et al. (2007) Systemic treatment with the antidiabetic drug metformin selectively impairs p53-deficient tumor cell growth. Cancer Res 67: 6745-6752. (Pubitemid 47105521)
38. Cantrell LA, Zhou C, Mendivil A, Malloy KM, Gehrig PA, et al. (2010) Metformin is a potent inhibitor of endometrial cancer cell proliferation- implications for a novel treatment strategy. Gynecol Oncol 116: 92-98.
39. Zhuang Y, Miskimins WK (2011) Metformin induces both caspase-dependent and poly(ADP-ribose) polymerase-dependent cell death in breast cancer cells Mol Cancer Res 9: 603-615.
40. Owen MR, Doran E, Halestrap AP (2000) Evidence that metformin exerts its anti-diabetic effects through inhibition of complex 1 of the mitochondrial respiratory chain. Biochem J 348: 607-614. (Pubitemid 30410251)
41. Sahra IB, Laurent K, Giuliano S, Larbret F, Ponzio G, et al. (2010) Targeting cancer cell metabolism: the combination of metformin and 2-deoxyglucose induces p53-dependent apoptosis in prostate cancer cells. Cancer Res 70: 2465-2475.
42. Faivre S, Kroemer G, Raymond E (2006) Current development of mTOR inhibitors as anticancer agents. Nat Rev Drug Discov 5: 671-688. (Pubitemid 44151605)
43. Guertin DA, Sabatini DM (2005) An expanding role for mTOR in cancer. Trends Mol Med 11: 353-361. (Pubitemid 41080576)
44. Mehta PK, Griendling KK (2007) Angiotensin II cell signaling: physiological and pathological effects in the cardiovascular system. Am J Physiol Cell Physiol 292: C82-C97. (Pubitemid 46127306)
45. Osório-Costa F, Rocha GZ, Dias MM, Carvalheira JBC (2009) Epidemiological and molecular mechanisms aspects linking obesity and cancer. Arq Bras Endocrinol Metabol 53: 213-226.
46. Pollak M (2008) Insulin and insulin-like growth factor signaling in neoplasia. Nat. Cancer Rev 8: 915-928.
47. Rocha GZ, Dias MM, Ropelle ER, Osório-Costa F, Rossato FA, et al. (2011) Metformin amplifies chemotherapy-induced AMPK activation and antitumoral growth. Clinical Cancer Research 17: 3993-4005.
48. Giannakou ME, Goss M, Junger MA, Hafen E, Leevers SJ, et al. (2004) Longlived Drosophila with overexpressed dFOXO in adult fat body. Science 305: 361. (Pubitemid 38938145)
49. Hwangbo DS, Gersham B, Tu MP, Palmer M, Tatar M (2004) Drosophila dFOXO controls lifespan and regulates insulin signaling in brain and fat body. Nature 429: 562-566. (Pubitemid 38737660)
50. Borkhardt A, Repp R, Haas OA, Leis T, Harbott J, et al. (1997) Cloning and characterization of AFX, the gene that fuses to MLL in acute leukemias with a t(X;11)(q13;q23). Oncogene 14: 195-202. (Pubitemid 27068305)
51. Paik JH, Kollipara R, Chu G, Ji H, Xiao Y, et al. (2007) FoxOs are lineagerestricted redundant tumor suppressors and regulate endothelial cell homeostasis. Cell 128: 309-323. (Pubitemid 46123514)
52. Hu MC, Lee DF, Xia W, Golfman LS, Ou-Yang F, et al. (2004) IkappaB kinase promotes tumorigenesis through inhibition of forkhead FOXO3a. Cell 117: 225-237. (Pubitemid 38496242)
53. Greer EL, Oskoui PR, Banko MR, Maniar JM, Gygi MP, et al. (2007) The energy sensor AMP-activated protein kinase directly regulates the mammalian FOXO3a transcription factor. J Biol Chem 282: 30107-30119. (Pubitemid 350035296)
54. Jagani Z, Singh A, Khosravi-Far R (2008) FoxO tumor suppressors and BCR-ABL-induced leukemia: a matter of evasion of apoptosis. Biochim Biophys Acta 1785: 63-84. (Pubitemid 350192084)
55. Seoane J, Le HV, Shen L, Anderson SA, Massagué J (2004) Integration of Smad and forkhead pathways in the control of neuroepithelial and glioblastoma cell proliferation. Cell 117: 211-223. (Pubitemid 38496241)
56. Trotman LC, Alimonti A, Scaglioni PP, Koutcher JA, Cordon-Cardo C, et al. (2006) Identification of a tumour suppressor network opposing nuclear Akt function. Nature 441: 523-527. (Pubitemid 44050155)
57. Fernández de Mattos S, Villalonga P, Clardy J, Lam EW (2008) FOXO3a mediates the cytotoxic effects of cisplatin in colon cancer cells. Mol Cancer Ther 7: 3237-3246.
58. Ho KK, Myatt SS, Lam EW (2008) Many forks in the path: cycling with FoxO. Oncogene 27: 2300-2311. (Pubitemid 351501781)
59. Alao JP (2007) The regulation of cyclin D1 degradation: roles in cancer development and the potential for therapeutic invention. Mol Cancer 6: 24.
60. Chen Y, Martinez LA, LaCava M, Coghlan L, Conti CJ (1998) Increased cell growth and tumorigenicity in human prostate LNCaP cells by overexpression to cyclin D1. Oncogene 16: 1913-1920. (Pubitemid 28200602)
61. Oltvai ZN, Milliman CL, Korsmeyer SJ (1993) Bcl-2 heterodimerizes in vivo with a conserved homolog, bax that accelerates programmed cell death. Cell 74: 609-619. (Pubitemid 23259742)
62. Reed JC (1997) Double identity for protein of Bcl-2 family. Nature 387: 773-778.
63. Zamzami N, Kroemer G (2001) The mitochondrion in apoptosis: how Pandora's box opens. Nat Rev Mol Cell Biol 2: 67-71. (Pubitemid 33676964)
64. Raisova M, Hossini AM, Eberle J, Riebeling C, Wieder T, et al. (2001) The Bax/Bcl-2 ratio determines the susceptibility of human melanoma cells to CD95/Fas-mediated apoptosis. J Invest Dermatol 117: 333-340. (Pubitemid 34205719)
65. Kroemer G (2000) Mitochondrial control of cell death. Nat Med 6: 513-519.
66. Youle RJ, Strasser A (2008) The BCL-2 protein family: opposing activities that mediate cell death. Nature Reviews 9:4759.
67. Cuvillier O, Nava VE, Murthy SK, Edsall LC, Levade T, et al. (2001) Sphingosine generation, cytochrome c release, and activation of caspase-7 in doxorubicin-induced apoptosis of MCF7 breast adenocarcinoma cells. Cell Death Differ 8: 162-171. (Pubitemid 32201364)
68. Gruning N, Ralser M (2011) Cancer Sacrifice for survival. Nature 480: 190-191.
69. Warburg O (1956) On the origin of cancer cells. Science 123: 309-314.
70. Anastasiou D, Poulogiannis G, Asara JM, Boxer MB, Jiang JK, et al. (2011) Inhibition of pyruvate kinase M2 by reactive oxygen species contributes to cellular antioxidant responses. Science 334: 1278-1283.
71. Davis RJ (2000) Signal transduction by the JNK group and MAP kinases. Cell 10: 239-252.
72. Robinson MJ, Cobb MH (1997) Mitogen-activated protein kinase pathways. Curr Opin Cell Biol 9: 180-186. (Pubitemid 27135985)
73. Han J, Ulcvitch RJ (1999) Emerging targets for anti-inflammatory therapy. Nat Cell Biol 1: E39-E40.
74. Schacffer HJ, Weber MJ (1999) Mitogen-activated protein kinases: specific messages from ubiquitinous messengers. Mol Cell Biol 19: 2435-2444.
75. DiPaola RS, Dvorzhinski D, Thalasila A, Garikapaty V, Doram D, et al. (2008) Therapeutic starvation and autophagy in prostate cancer: a new paradigm for targeting metabolism in cancer therapy. Prostate 68: 1743-1752.